OrbiMed
Venture capitalNew York · Pre-Seed–Late Stage · 122 people tracked
Also known as ORBIMED ADVISORS LLC
Investment thesis
OrbiMed invests globally across the healthcare industry, backing companies from early-stage private ventures to large multinational corporations. Its focus spans biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services, with the aim of supporting innovations that help people live healthier, longer, and more productive lives. The firm brings tailored financing solutions alongside global team resources drawn from scientific, medical, and investment professionals to help build world-class healthcare companies.
Source: firm website, verified Aug 3, 2026.
Team · 122 people
from the firm's website & public directories
What they invest in
from 93 of 275 portfolio companiesBiotech ×74Healthtech ×30Medical Devices ×28AI & Machine Learning ×11Digital Health ×9Deep Tech ×6Enterprise Software ×3SaaS ×3
HQs:United States×81Australia×1United Kingdom×1India×1
Investments · 275 tracked
founders shown can be your intro pathScribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)Vijay Pande(Director)
Aadi Bioscience is a commercial-stage biopharmaceutical company developing therapies for cancer patients with mTOR pathway driver alterations, with an initial focus on advanced malignant PEComa, an ultra-rare cancer.
BiotechHealthtechMorristown, US
Baiteng Zhao(Director)Scott Giacobello(Executive Officer)Caley Castelein(Director)Richard Maroun(Director)Bryan Ball(Executive Officer)Behzad Aghazadeh(Director)
Board seatChau Khuong· per SEC Form D · $41.8M raise · filed Mar 2017
BiotechMenlo Park, US
Nathan Hubbard(Executive Officer)Aya Jakobovits(Executive Officer, Director)Jonathan Silverstein(Director)Carl Gordon(Director)Florent Gros(Director)Erez Chimovits(Director)
Board seatJonathan SilversteinCarl Gordon· per SEC Form D
Arvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degrader therapies for oncology and neurology.
BiotechNew Haven, US
Stephen Squinto(Director)Liam Ratcliffe(Director)Andrew Levin(Director)Sean Cassidy(Executive Officer)Jonathan Soderstrom(Director)Brad Margus(Director)
Board seatStephen Squinto· per SEC Form D · $55M raise · filed Apr 2018
BiotechLa Jolla, US
Eric W. Roberts(Executive Officer, Director)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Kenneth A. Stauderman(Executive Officer)Sudarshan Hebbar(Executive Officer)Eric Bjerkholt(Director)
Board seatChau Khuong· per SEC Form D · $80M raise · filed Aug 2019
BiotechTel Aviv
Neil Harris Cohen(Director)Jill Quigley(Director)Sigal Fattal(Executive Officer)Adi Mor(Executive Officer, Director)Alan Charles Moses(Director)Matthew Frankel(Executive Officer)
Board seatStephen Squinto· per SEC Form D · $45.4M raise · filed Mar 2021
Cambridge, US
Board seatStephen SquintoCarl Gordon· per SEC Form D
BiotechCambridge, US
Sara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)Mette Kirstine Agger(Director)James G. McArthur(Executive Officer, Director)
Board seatDavid Bonita· per SEC Form D · $63M raise · filed Mar 2019
BiotechLexington, US
Jasbir S. Seehra(Executive Officer, Director)Julius Knowles(Director)Alon Lazarus(Director)Ohad Hammer(Director)Ran Nussbaum(Director)
Board seatCarl Gordon· per SEC Form D · $56M raise · filed Mar 2020
BiotechAustin, US
Matthew Winkler(Director)Michael Powell(Director)Clay Siegall(Director)Sinil Kim(Executive Officer)Paul Lammers(Executive Officer, Director)Jon Irvin(Executive Officer)
Board seatChau Khuong· per SEC Form D · $80M raise · filed Jun 2019
Prelude Therapeutics develops precision oncology medicines, including selective KAT6A degraders, mutant-selective JAK2 inhibitors, and degrader antibody conjugates for cancer treatment.
AI & Machine LearningBiotechMedical DevicesNewark, US
Krishna Vaddi(Executive Officer, Director)Paul Friedman(Director of Issuer)
Board seatDavid Bonita· per SEC Form D
BiotechBoston, US
Edward T. Mathers(Director)David J. McGirr(Director)Jonathan Silverstein(Director)Keith Gottesdiener(Executive Officer, Director)David P. Meeker, M.D.(Director)Neil Exter(Director)
Board seatJonathan Silverstein· per SEC Form D · $40M raise · filed Dec 2015
San Jose, US
Jeffrey W. Dunn(Executive Officer, Director)Mark Reiley(Director)Timothy E. Davis(Director)John G. Freund(Director)David Bonita(Director)Karen A. Licitra(Director)
Board seatDavid Bonita· per SEC Form D · $21M raise · filed Jun 2016
BiotechSouth San Francisco, US
Kirk Ways(Director)Javier Szwarcberg(Executive Officer, Director)Simpson Camilla(Director)Percival Barretto-Ko(Director)Tiba Aynechi(Director)Samir Gharib(Executive Officer)
Board seatDina Chaya· per SEC Form D · $53.6M raise · filed Feb 2023
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Ed Mathers(Director)Chau Khuong(Director)Bharatt Chowrira(Executive Officer)Ankit Mahadevia(Director)Michael Sheahan(Executive Officer)Peter Barrett(Director)
Board seatChau Khuong· per SEC Form D · $42M raise · filed May 2017
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Timothy Mayer(Executive Officer)Michael Richman(Executive Officer, Director)Elaine V. Jones(Director)Udayan Guha(Executive Officer)Anne Borgman(Director)Steven P. Cobourn(Executive Officer)
Board seatChau Khuong· per SEC Form D · $93.4M raise · filed Nov 2018
Adaptive Biotechnologies decodes the genetic patterns of the adaptive immune system to develop clinical products for diagnosing and treating disease.
BiotechDigital HealthHealthtechMedical DevicesSeattle, US
Arnold Levine(Director)Chad Robins(Executive Officer, Director)Andris Zoltners(Director)Tom Willis(Director)Kathleen Determann(Executive Officer)Peter Neupert(Director)
Clinical-stage biopharmaceutical company focused on identifying, developing and commercializing differentiated medicines for cancer patients.
BiotechMedical DevicesNewtown Square, US
Brent Rice(Chief Commercial Officer)Jason Zhang(Director)Cong Xu(Director)Zhengbin (Bing) Yao(Executive Officer, Director)Stuart Lutzker(Director)
Aura Biosciences develops targeted oncology therapies based on a virus-like drug conjugate (VDC) technology platform, aimed at cancers with high unmet need.
BiotechMedical DevicesCambridge, US
Raj Parekh, Ph.D.(Director)Michael Wyzga(Executive Officer)Joel Jean-Mairet, Ph.D.(Director)Jose' Baselga, Ph.D.(Director)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)
AVITA Medical develops therapeutic acute wound care technologies, including the FDA-approved RECELL System that uses a patient's own skin to create a Spray-On Skin cell suspension for treating thermal burn wounds and full-thickness skin defects.
BiotechHealthtechMedical Devices
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Eric Morgen(Director)Dov Goldstein(Executive Officer)Jason Coloma(Director)Kristen Fortney(Executive Officer, Director)
Caris Lifesciences operates a precision oncology platform that analyzes DNA, RNA and proteins across tissue and blood to profile a patient's cancer and match treatments and clinical trials.
AI & Machine LearningBiotechHealthtech
David Dean Halbert(Chairman, Founder and CEO)
BiotechGaithersburg, US
George J. Joulwan(Director)Robert G Kramer(Executive Officer)Ronald B Richard(Director)Katherine Strei(Executive Officer)Fuad El-Hibri(Director, Executive Officer)Adam R Havey(Executive Officer)
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices<UNKNOWN>, US
BiotechHealthtechMiami, US
Raymond Cohen(Director)Thomas J. Kester(Director)Scott R. Ward(Director)Patrick Verta(Executive Officer)Kathryn Arnold(Director)Pete Ligotti(Executive Officer)
BiotechAustin, US
Walter Loewenbaum(Director)Josiah Hornblower(President/CEO)
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergTIMOTHY BARBERICH(Director)ALISON LAWTON(Director)ERIC ROWINSKY(Director)BRUCE WENDEL(Director)GINA CONSYLMAN(Director)
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices<UNKNOWN>, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.
BiotechDeep TechHealthtech
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.
BiotechMedical DevicesNew York, US
Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)
HealthtechCarlsbad, US
Aditya Puri(Director)Steven Hochberg(Director)Vince Burgess(Director)David Bonita(Director)Christoph Scharf(Director)Randy Werneth(Executive Officer, Director)
Board seatDavid Bonita· per SEC Form D
BiotechFoster City, US
Maneesh Jain(Director, Promoter)Daniel Diniz De Carvalho(Executive Officer, Promoter)Anne-Renee Hartman(Executive Officer)Alan Williams(Executive Officer)Lisa Alderson(Executive Officer, Director)Priscilla Huang(Executive Officer)
Board seatDavid Bonita· per SEC Form D · $5M raise · filed Apr 2026
BiotechCincinnati, US
Reinhard Ambros(Director)Duane Nash(Director)Paul Weiss(Director)Muneer Satter(Director)Adrienne Graves(Director)Joseph H. Gardner(Executive Officer)
Board seatChau Khuong· per SEC Form D · $9.2M raise · filed Apr 2016
Clinical-stage company developing novel treatment for recurrent high-grade gliomas
HealthtechChanhassen, US
Klaus Veitinger(Director)Imran Eba(Executive Officer)Conrad Wang(Director)Juan-Pablo Mas(Director)Jeremy Ling(Executive Officer)Robert Stein(Director)
Board seatKlaus Veitinger· per SEC Form D · $67M raise · filed Jul 2026
Angiex is a biotech company developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) that target the intracellular transporter TM4SF1, which is expressed across solid cancers.
BiotechHealthtechMedical DevicesCambridge, US
Jonathan Adams(Director)Errik Anderson(Director)Jason Camm(Director)Fabian Hansen(Director)Paul Jaminet(Executive Officer, Director)Amal Amin(Director)
Board seatIain Dukes· per SEC Form D · $28.4M raise · filed Sep 2025
BiotechSan Francisco, US
Jonathan Silverstein(Director)Steve Squinto(Director)Kush Parmar(Director)Jonathan Leff(Director)Matthew Patterson(Executive Officer, Director)Thomas Woiwode(Director)
Board seatJonathan Silverstein· per SEC Form D · filed Sep 2015
HealthtechWatertown, US
Thomas Barnes(Chief Executive Officer/President)Roy Amariglio(Director)Nick Olsen(Director)Stephen Squinto(Director)Richard Morris(Chief Financial Officer)Michal Silverberg(Director)
Board seatStephen Squinto· per SEC Form D · $85M raise · filed Mar 2026
New York, US
Tania Dimitrova(Executive Officer)Megan Dow(Executive Officer)StJohn Donnie McGrath(Executive Officer, Director)
BoardBo Chen(Director)Carl Gordon(Director)David Wang(Director)
Board seatCarl Gordon· per SEC Form D · $55M raise · filed Jul 2024
BiotechLaval
Francois Desjardins(Vice President, Finance)Denis Garceau(Senior Vice President, Drug Development)Franklin Berger(Director)Roberto Bellini(President and Chief Executive Officer)Joseph Rus(Director)Youssef L. Bennani(Director)
Board seatChau Khuong· per SEC Form D · $24M raise · filed Jan 2019
BiotechWestminster, US
Andrew J. Tofe(Director)Britt Pearson(Executive Officer)Jonathan Silverstein(Director)Chau Khuong(Director)Jeff Marx(Executive Officer)Glen Kashuba(Executive Officer, Director)
Board seatChau KhuongJonathan Silverstein· per SEC Form D · $4M raise · filed Feb 2015
BiotechDorval
Francois Nader(Director)Donna Roy Grogan(Executive Officer)Jean-Francois Pariseau(Executive Officer, Director)Michael Singer(Executive Officer)David P. Bonita(Director)Robert Heft(Director)
Board seatDavid Bonita· per SEC Form D · $60M raise · filed Jul 2015
Bothell, US
Board seatTal Zaks· per SEC Form D · $84.8M raise · filed Mar 2025
La Jolla, US
Board seatStephen Squinto· per SEC Form D · $15M raise · filed Sep 2025
BiotechPhiladelphia, US
Kim Blackwell(Director)Michael Byrnes(Director)Erez Chimovits(Director)Giovanni Mariggi(Director)Dieter Weinand(Director)William Hinshaw(Executive Officer, Director)
Board seatErez Chimovits· per SEC Form D · $46M raise · filed May 2025
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)Jason Rhodes(Director)Carl Gordon(Director)
BoardJean George(Director)
Board seatCarl Gordon· per SEC Form D · $2M raise · filed May 2016
BiotechPennington, US
Chris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)Chau Khuong(Director)Gary Sender(Director)Stephen Squinto(Executive Officer, Director, Promoter)Dale Ludwig(Mr. Ludwig is the Chief Scientific Officer)Julie Hambleton(Director)
Board seatChau Khuong· per SEC Form D · $55M raise · filed Dec 2021
BiotechBurlingame, US
Robert Schreiber(Director)John Celebi(Executive Officer)John Diekman(Director)Mark Goldsmith(Director)Carl Gordon(Director)David Goeddel(Director)
Board seatCarl Gordon· per SEC Form D · $6.3M raise · filed Jan 2015
BiotechBoston, US
Richard Wooster(Director)Jotin Marango(Executive Officer)Jean-Francois Formela(Director)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Owen Hughes(Director)
Board seatIain DukesDavid Bonita· per SEC Form D · $75M raise · filed Jul 2025
Healthtech
Jerry Griffin(Director)Timothy Herbert(Executive Officer, Director)Gary Brothers(Director)Mudit Jain(Director)Marilyn Nelson(Director)Joyce Erony(Director)
Board seatChau Khuong· per SEC Form D · $37.5M raise · filed Nov 2016
Woburn, US
Board seatKevin KochKlaus Veitinger· per SEC Form D · filed Jul 2021
Browse all 275 investments with full details →
▶75 more tracked companies
MyfridoMyriadNanotronicsNerre TherapeuticsNeurelisNeurogastrxNewmedNoctrix HealthNorchem PharmaNucleixNucleusradOdyssey TherapeuticsOttimopharmaPathaiPathalysPeesafePerfusetherapeuticsPic TherapeuticsPinnaclePMV PharmaProlynxincProVerumPulnovomedQuantxbioRadiuspharmRampartbioRayTheraRecodetxReliabiotechRenasant BioRenasantbioReparerxShattucklabsSidewinderbioSikkasoftSionnatxSiriusrnaSitalaSneuroSpectronrxStairmedStar SportsmedStar TherapeuticsStratustxSurakshanetTandemaiTelabioTendfoTerremotobioThe Oncology InstituteThumbnail for Rapt TherapeuticsTigerConnectTopaz TxTrisaluslifesciTriveniTrunativTurnstone BiologicsTyto CareUquifaVanquabioVariantyxVelosBioVelseraVerdiva BioVerricavisit www.cytomx.comVivacta BioVvardisWhaleimagingWindward BioYarrowbioscienceZaiZenteratxZionpharmaZyloxtb
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 10
as of Sep 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| OrbiMed Private Investments IX, LPLPs: California State Teachers' Retirement System, New Mexico Educational Retirement Board, Kern County Employees' Retirement Association | 2022 | — | 29.3% | 1.16x | 0.21x |
| OrbiMed Royalty & Credit Opportunities IVLPs: California State Teachers' Retirement System, Sacramento County Employees' Retirement System, Kern County Employees' Retirement Association | 2022 | — | 14.1% | 1.28x | 0.25x |
| OrbiMed Private Investments VIII, L.P.LPs: California State Teachers' Retirement System, New Mexico Educational Retirement Board | 2020 | — | 6.9% | 1.19x | 0.30x |
| OrbiMed Royalty & Credit Opportunities III, LPLPs: California State Teachers' Retirement System, Sacramento County Employees' Retirement System | 2019 | — | 15.1% | 1.20x | 0.95x |
| OrbiMed Private Investments VILPs: Oregon Public Employees Retirement System | 2015 | — | 13.0% | 1.64x | 1.18x |
| OrbiMed Private Investments VLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System | 2013 | — | 38.2% | 2.35x | 2.14x |
| OrbiMed Private Investments IVLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System, The Regents of the University of California +1 more | 2009 | — | 31.8% | 2.73x | 2.72x |
| Orbimed Private lnvesuncnts IV, L PLPs: The Regents of the University of California | 2009 | — | 36.2% | 2.67x | 0.45x |
| Orbimed Private Investments III, LPLPs: The Regents of the University of California | 2006 | — | 18.1% | 2.34x | 1.48x |
| Orbimed Private lnvesunents Ill, LPLPs: The Regents of the University of California | 2006 | — | 18.4% | 2.32x | — |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does OrbiMed invest at?
- OrbiMed invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is OrbiMed's typical check size?
- OrbiMed typically writes checks of $1M – $75M.
- What sectors does OrbiMed focus on?
- OrbiMed focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is OrbiMed located?
- OrbiMed is headquartered in New York, US.
- Does OrbiMed lead rounds?
- Yes, OrbiMed leads investment rounds.
Media · Podcasts & interviews
featuring the teamGeoffrey C. Hsu, CFA, General Partner, OrbiMed Advisors LLC
Biotechnology Innovation Organization · Geoffrey C. Hsu
Co-investors · 88
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Avoro Capital Advisors is an investment firm focused on healthcare and life sciences, pursuing scientific breakthroughs that address unmet medical needs.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
▶76 more co-investors
5AM VenturesPfizer Venture InvestmentsAdvent Life SciencesAndreessen HorowitzUS Venture PartnersVida VenturesGeneral CatalystNew Enterprise Associates (NEA)SR One Capital ManagementDeerfield Management CompanyAisling CapitalHatteras Venture PartnersLongwood FundGV (Google Ventures)Menlo VenturesOUP (Osage University Partners)Versant VenturesThe Column GroupThird Rock VenturesSV Health InvestorsAndera PartnersYsios CapitalSamsara BioCapitalRiverVest Venture PartnersWestlake Village BioPartnersFounders FundLightspeed Venture PartnersBessemer Venture PartnersKhosla VenturesKleiner PerkinsCRV (Charles River Ventures)Tiger Global ManagementTrinity VenturesPear VCDimension CapitalSofinnova PartnersDomain AssociatesAbingworthMPM CapitalOmega FundsAction Potential Venture Capital Ltd.RTW Investments L.P.Signet Healthcare PartnersSequoia CapitalDCVC (Data Collective)Meritech Capital PartnersVenrockPolaris PartnersGeneral AtlanticZetta Venture PartnersWildcat Venture PartnersM12 (Microsoft's Venture Fund)BDC Venture CapitalPitangoEQT Life SciencesForbionPivotal bioVenture PartnersFlagship PioneeringFrazier Healthcare PartnersTencent Holdings6 Dimensions CapitalNew Leaf Venture Partners1955 CapitalCofounders Capital+ND CapitalDFJRiverVest VentureSeroba Life SciencesJMI EquityAmplitude Venture CapitalBorealis VenturesHBM PartnersACORN BIOVENTURESCincyTechDe Novo VenturesWelsh, Carson, Anderson & Stowe
Firms observed investing alongside OrbiMed, from public investor directories. Shared companies are the overlap with OrbiMed's recorded portfolio.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.